Haemonetics Corporation — Form 10-Q Summary
Business context and reporting period
Haemonetics provides medical products and solutions for blood and plasma collection, surgical care, and hospital transfusion services. It reports three segments: Plasma, Blood Center, and Hospital. This filing covers the three months ended July 1, 2023, the first quarter of fiscal 2024; the comparable period ended July 2, 2022. The fiscal year ends March 30, 2024.
Financial performance and liquidity
| Metric | Quarter ended July 1, 2023 | Prior-year quarter | Change |
|---|---|---|---|
| Revenue | $311.3 million | $261.5 million | +19.1%; +20.5% constant currency |
| Gross profit / margin | $167.3 million / 53.7% | $142.3 million / 54.4% | Profit +17.6%; margin down 0.7 percentage points |
| Operating income / margin | $53.7 million / 17.2% | $30.8 million / 11.8% | Income +74.4% |
| Net income | $41.0 million | $19.9 million | +106.5% |
| Diluted EPS | $0.80 | $0.38 | +110.5% |
| Operating cash flow | $19.1 million | $42.0 million | Down $22.9 million |
Revenue growth was led by Plasma and Hospital. Plasma revenue rose 35.4% (35.5% constant currency), Hospital rose 12.6% (13.8% constant currency), and Blood Center rose 2.5% (5.8% constant currency). U.S. revenue increased 30.3%; international revenue declined 6.5% reported, or 2.7% constant currency. Management attributed overall growth mainly to volume and pricing in Plasma and Hospital.
Gross margin declined despite higher gross profit, with mix, volume, and pricing benefits partly offset by inventory reserves, operating investment, and higher depreciation. Operating income benefited from stronger Plasma and Hospital revenue; corporate expenses were lower, while growth investment, foreign exchange, ERP digital-transformation costs, and depreciation were offsets. Net income also benefited from lower net interest and other expense, partly reflecting higher interest income.
Cash and cash equivalents were $285.7 million at July 1, 2023, versus $284.5 million at April 1. Working capital was $564.7 million, the current ratio was 3.4, and the company reported a net-debt position of $479.2 million (debt less cash). Balance-sheet debt was approximately $765.0 million, including $751.4 million long-term and $13.6 million current; this includes $500 million principal of 0% convertible notes due 2026 and a $273.0 million term loan. The term loan carried a 6.6% effective rate. No revolving-credit borrowings were outstanding; $420 million of revolving capacity was available, subject to the facility’s terms. The company said available liquidity sources were sufficient for at least the next 12 months and was in compliance with debt covenants.
Operating cash flow fell primarily because inventory increased, partly offset by higher net income. Investing cash use was $15.3 million, compared with $58.2 million a year earlier, mainly due to lower capital expenditures; financing cash use was $0.6 million. Ending cash increased $1.3 million. Inventory rose to $289.2 million from $259.4 million.
Material changes, outlook, and risks
- Management expects aggregate Operational Excellence Program charges of $95 million to $105 million through fiscal 2025; cumulative charges were $69.4 million, with $2.2 million of restructuring and related costs in the quarter.
- A supply agreement with CSL was extended through December 2025. CSL’s minimum purchase commitment slightly exceeds $100 million in fiscal 2024; management expects CSL to remain a meaningful Plasma revenue contributor in fiscal 2025.
- The filing provides no specific consolidated full-year revenue or earnings guidance. Management cited growth potential in Plasma and Hospital, while describing Blood Center as a challenging market requiring cost reductions, a narrower product scope, and review of unfavorable customer contracts.
- The filing reports a voluntary recall, issued in August 2023, of certain Whole Blood products sold in the U.S. and certain foreign jurisdictions. It says a $3.4 million inventory charge related to the recall was recorded in fiscal Q1 and that additional charges may follow. The recall occurred after the quarter-end, so investors should review the subsequent-event disclosure and any later updates.
- Risks include product quality and recall exposure, regulatory requirements, customer concentration in Plasma, supply and raw-material availability and costs, foreign-exchange and variable-rate interest exposure, and litigation. The company recorded additional loss contingencies in the quarter for a federal qui tam matter and an Illinois biometric-information class action; neither had a material financial-statement impact. The filing reports no material change to previously disclosed risk factors.
Most important facts for investors to verify
- Whether Whole Blood recall costs or operational effects increased after the reported $3.4 million charge.
- Whether Plasma growth and CSL purchase commitments translate into sustained revenue and margin performance, and how much growth depends on pricing and volume.
- Whether inventory levels normalize and operating cash flow improves after the quarter’s inventory-related cash use.
- Debt service, covenant headroom, and the effect of variable rates; the filing estimates a 100-basis-point Term SOFR increase would add $0.5 million of annual interest expense.
- Developments and potential costs in the DOJ/qui tam and Illinois biometric-information matters, along with progress and remaining costs under the restructuring program.